ACM

Aisling Capital Management Portfolio holdings

AUM $360M
This Quarter Return
+1.31%
1 Year Return
+114.67%
3 Year Return
+1,171.46%
5 Year Return
+892.24%
10 Year Return
–
AUM
$204M
AUM Growth
+$204M
Cap. Flow
+$0
Cap. Flow %
0%
Top 10 Hldgs %
97.39%
Holding
16
New
–
Increased
–
Reduced
–
Closed
–

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$9.89B
$104M 51.13% 6,068,125 – –
VRNA
2
Verona Pharma
VRNA
$9.16B
$23.6M 11.55% 1,115,352 – –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.41B
$21.5M 10.51% 1,025,000 – –
BMEA icon
4
Biomea Fusion
BMEA
$116M
$17.5M 8.59% 798,757 – –
GLUE icon
5
Monte Rosa Therapeutics
GLUE
$296M
$10.1M 4.94% 1,472,331 – –
OKUR
6
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
$5.81M 2.85% 886,075 – –
NUVB icon
7
Nuvation Bio
NUVB
$1.02B
$4.57M 2.24% 2,541,009 – –
ACRS icon
8
Aclaris Therapeutics
ACRS
$209M
$4.51M 2.21% 434,455 – –
ELEV
9
DELISTED
Elevation Oncology
ELEV
$4.31M 2.11% 2,834,910 – –
SPRB
10
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
$2.59M 1.27% 1,205,511 – –
PSTX
11
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$1.84M 0.9% 1,043,267 – –
MRKR icon
12
Marker Therapeutics
MRKR
$12M
$974K 0.48% 314,286 – –
TECX
13
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
$959K 0.47% 1,009,779 – –
SYRE icon
14
Spyre Therapeutics
SYRE
$996M
$762K 0.37% 1,691,151 – –
VIRX
15
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$407K 0.2% 288,571 – –
BCEL
16
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$380K 0.19% 387,653 – –